Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer.
Journal:
Frontiers in immunology
PMID:
40170854
Abstract
BACKGROUND: Breast cancer, a heterogeneous malignancy, comprises multiple subtypes and poses a substantial threat to women's health globally. Neoadjuvant therapy (NAT), administered prior to surgery, is integral to breast cancer treatment strategies. It aims to downsize tumors, optimize surgical outcomes, and evaluate tumor responsiveness to treatment. However, accurately predicting NAT efficacy remains challenging due to the disease's complexity and the diverse responses across different molecular subtypes.